Fulltext

An in vitro potency assay using nicotinic acetylcholine receptor binding works well with antivenoms against Bungarus candidus and Naja naja

Ratanabanangkoon K 1 , Simsiriwong P 2 , Pruksaphon K 3 , Tan KY 4 , Chantrathonkul B 2 , Eursakun S 2 Show all authors , Tan CH 5

Affiliations 

  • 1 Laboratory of Immunology, Chulabhorn Research Institute, Bangkok, 10210, Thailand. [email protected]
  • 2 Laboratory of Immunology, Chulabhorn Research Institute, Bangkok, 10210, Thailand
  • 3 Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand
  • 4 Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
  • 5 Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. [email protected]
Sci Rep, 2018 06 26;8(1):9716.
PMID: 29946111 DOI: 10.1038/s41598-018-27794-3

Abstract

In order to facilitate/expedite the production of effective and affordable snake antivenoms, a novel in vitro potency assay was previously developed. The assay is based on an antiserum's ability to bind to postsynaptic neurotoxin (PSNT) and thereby inhibit the PSNT binding to the nicotinic acetylcholine receptor (nAChR). The assay was shown to work well with antiserum against Thai Naja kaouthia which produces predominantly the lethal PSNTs. In this work, the assay is demonstrated to work well with antiserum/antivenom against Bungarus candidus (BC), which also produces lethal presynaptic neurotoxins, as well as antivenom against Sri Lankan Naja naja (NN), which produces an abundance of cytotoxins. The in vitro and in vivo median effective ratios (ER50s) for various batches of antisera against BC showed a correlation (R2) of 0.8922 (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications